Profile data is unavailable for this security.
About the company
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
- Revenue in USD (TTM)--
- Net income in USD--
- Incorporated2021
- Employees49.00
- LocationGH Research PLCJoshua Dawson House, Dawson StreetDublin D02 RY95IrelandIRL
- Phone+353 14378334
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lyell Immunopharma Inc | 54.00k | -210.26m | 312.32m | 224.00 | -- | 0.5512 | -- | 5,783.77 | -0.8297 | -0.8297 | 0.0002 | 2.21 | 0.00007 | -- | -- | 241.07 | -28.23 | -- | -29.53 | -- | -- | -- | -389,368.50 | -- | -- | -- | 0.00 | -- | -99.85 | -- | -28.13 | -- | -- | -- |
Korro Bio Inc | 0.00 | -92.22m | 312.35m | 92.00 | -- | 1.57 | -- | -- | -30.51 | -30.51 | 0.00 | 21.34 | 0.00 | -- | -- | 0.00 | -56.06 | -31.55 | -59.82 | -36.48 | -- | -- | -- | -365.87 | -- | -167.13 | 0.00 | -- | -- | -- | 0.5001 | -- | 78.21 | -- |
Monte Rosa Therapeutics Inc | 5.76m | -130.41m | 312.39m | 103.00 | -- | 1.39 | -- | 54.24 | -2.24 | -2.24 | 0.0967 | 3.66 | 0.0185 | -- | 1.05 | 43,300.75 | -41.88 | -- | -46.47 | -- | -- | -- | -2,264.53 | -- | -- | -- | 0.00 | -- | -- | -- | -24.75 | -- | -- | -- |
Instil Bio Inc | 0.00 | -119.58m | 315.31m | 49.00 | -- | 1.62 | -- | -- | -18.39 | -18.39 | 0.00 | 29.98 | 0.00 | -- | -- | 0.00 | -34.04 | -- | -35.48 | -- | -- | -- | -- | -- | -- | -- | 0.2958 | -- | -- | -- | 30.06 | -- | -- | -- |
Aldeyra Therapeutics Inc | 0.00 | -37.87m | 317.31m | 10.00 | -- | 3.23 | -- | -- | -0.6387 | -0.6387 | 0.00 | 1.65 | 0.00 | -- | -- | 0.00 | -26.89 | -36.79 | -31.76 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1342 | -- | -- | -- | 39.47 | -- | -- | -- |
ADC Therapeutics SA | 66.75m | -214.86m | 318.10m | 273.00 | -- | -- | -- | 4.77 | -2.55 | -2.55 | 0.7802 | -1.36 | 0.1519 | 0.2704 | 2.86 | 244,490.80 | -47.51 | -48.41 | -56.37 | -55.63 | 92.99 | -- | -312.84 | -308.62 | 5.90 | -4.63 | 1.44 | -- | -66.86 | 127.56 | -52.78 | -- | 5.42 | -- |
MeiraGTx Holdings PLC | 8.12m | -93.14m | 320.31m | 387.00 | -- | 3.35 | -- | 39.44 | -1.49 | -1.49 | 0.1298 | 1.24 | 0.0282 | -- | 0.4733 | 19,384.25 | -32.29 | -26.40 | -40.66 | -32.66 | -- | -- | -1,146.81 | -420.70 | -- | -22.76 | 0.4759 | -- | -11.95 | -- | 35.17 | -- | 12.37 | -- |
Heron Therapeutics Inc | 136.36m | -48.13m | 321.54m | 126.00 | -- | -- | -- | 2.36 | -0.3249 | -0.3249 | 0.9094 | -0.2503 | 0.6503 | 1.08 | 1.81 | 1,082,230.00 | -22.95 | -53.55 | -38.15 | -71.24 | 65.49 | 52.52 | -35.29 | -170.12 | 1.85 | -- | 1.34 | -- | 17.99 | 10.40 | 39.26 | -- | -29.97 | -- |
XOMA Royalty Corp | 15.24m | -25.10m | 323.51m | 13.00 | -- | 3.22 | -- | 21.23 | -2.22 | -2.22 | 1.17 | 8.58 | 0.0826 | -- | 21.36 | 1,172,231.00 | -9.88 | -4.55 | -10.62 | -4.94 | -- | -- | -119.61 | -31.87 | -- | -- | 0.5471 | -- | -21.06 | -2.13 | -105.10 | -- | 23.16 | -- |
Inozyme Pharma Inc | 0.00 | -88.56m | 324.34m | 59.00 | -- | 3.40 | -- | -- | -1.46 | -1.46 | 0.00 | 1.52 | 0.00 | -- | -- | 0.00 | -57.76 | -45.00 | -63.48 | -48.90 | -- | -- | -- | -- | -- | -- | 0.3244 | -- | -- | -- | -6.13 | -- | 2.85 | -- |
AC Immune SA | 18.05m | -70.52m | 334.42m | 133.00 | -- | 2.33 | -- | 18.53 | -0.748 | -0.748 | 0.1949 | 1.45 | 0.0787 | -- | 28.76 | 135,723.90 | -30.73 | -18.25 | -42.90 | -19.52 | -- | -- | -390.68 | -148.29 | -- | -128.01 | 0.0255 | -- | 276.14 | 15.52 | 23.35 | -- | -15.49 | -- |
GH Research PLC | -100.00bn | -100.00bn | 337.66m | 49.00 | -- | 1.70 | -- | -- | -- | -- | -- | 3.82 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0038 | -- | -- | -- | -58.47 | -- | -- | -- |
Nautilus Biotechnology Inc | 0.00 | -69.64m | 339.86m | 164.00 | -- | 1.44 | -- | -- | -0.557 | -0.557 | 0.00 | 1.88 | 0.00 | -- | -- | 0.00 | -23.08 | -- | -23.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.93 | -- | -- | -- |
Climb Bio Inc | 0.00 | -64.20m | 346.03m | 9.00 | -- | 1.55 | -- | -- | -2.15 | -2.15 | 0.00 | 3.33 | 0.00 | -- | -- | 0.00 | -37.51 | -- | -38.33 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
Corvus Pharmaceuticals Inc | 0.00 | -22.62m | 352.79m | 28.00 | -- | 6.89 | -- | -- | -0.4458 | -0.4458 | 0.00 | 0.8189 | 0.00 | -- | -- | 0.00 | -36.89 | -38.31 | -44.60 | -43.34 | -- | -- | -- | -- | -- | -22.18 | 0.00 | -- | -- | -- | 34.57 | -- | -37.45 | -- |
Holder | Shares | % Held |
---|---|---|
BVF Partners LPas of 31 Mar 2024 | 10.40m | 19.99% |
RA Capital Management LPas of 31 Mar 2024 | 6.25m | 12.02% |
RTW Investments LPas of 31 Mar 2024 | 3.33m | 6.40% |
Lynx1 Capital Management LPas of 31 Mar 2024 | 3.31m | 6.36% |
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 3.02m | 5.80% |
Verition Fund Management LLCas of 31 Mar 2024 | 1.13m | 2.17% |
Cormorant Asset Management LPas of 31 Mar 2024 | 593.04k | 1.14% |
Morgan Stanley Investment Management, Inc.as of 31 Mar 2024 | 279.14k | 0.54% |
Checkpoint Capital LPas of 31 Mar 2024 | 185.65k | 0.36% |
Apo Asset Management GmbHas of 30 Sep 2023 | 120.90k | 0.23% |